Scientists test COVID drug safety in people with kidney issues
NCT ID NCT06698549
Summary
This early study tested how a potential COVID-19 drug, ALG-097558, is processed in the body of people with and without severe kidney problems. It involved 12 participants who took the drug orally twice a day. The main goal was to understand if kidney function changes how the drug moves through and leaves the body, which is important for determining safe doses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Genesis Clinical Trials
Tampa, Florida, 33603, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.